Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 102
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: L1B518BD883EN
Leaflet:

Download PDF Leaflet

Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2016
Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leishmaniasis (Kala-Azar) – Pipeline Review, H2 2016, provides an overview of the Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline landscape.

Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen and fever. Treatment includes anti-parasitic drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Leishmaniasis (Kala-Azar) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 3, 11, 6 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 11 and 8 molecules, respectively.Leishmaniasis (Kala-Azar).

Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Leishmaniasis (Kala-Azar) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Leishmaniasis (Kala-Azar) Overview
Therapeutics Development
Pipeline Products for Leishmaniasis (Kala-Azar) - Overview
Pipeline Products for Leishmaniasis (Kala-Azar) - Comparative Analysis
Leishmaniasis (Kala-Azar) - Therapeutics under Development by Companies
Leishmaniasis (Kala-Azar) - Therapeutics under Investigation by Universities/Institutes
Leishmaniasis (Kala-Azar) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Leishmaniasis (Kala-Azar) - Products under Development by Companies
Leishmaniasis (Kala-Azar) - Products under Investigation by Universities/Institutes
Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development
Advinus Therapeutics Ltd
BioLingus AG
iCo Therapeutics Inc.
Laboratorios LETI S.L.
ManRos Therapeutics
Matinas BioPharma Holdings, Inc.
Nanomerics Ltd
Novartis AG
Oblita Therapeutics BVBA
Leishmaniasis (Kala-Azar) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(gentamicin sulfate + paromomycin sulfate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

18-MC - DRUG PROFILE

Product Description
Mechanism Of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Amphotericin B sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
candicidin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CDRI-99288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Leishmaniasis and Trypanosomiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNF-6702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hypoestoxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon gamma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KVH-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leishmaniasis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leishmaniasis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leishmaniasis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leishmaniasis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leishmaniasis vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPC-1161B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-MAPA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-010269 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SJL-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Leishmaniasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Leishmaniasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Visceral Leishmaniasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Leishmaniasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Leishmaniasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Visceral Leishmaniasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Visceral Leishmaniasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block LHR1 for Leishmaniasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease and Leishmaniasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Leishmania Major Casein Kinase 1 Isoform 2 for Leishmaniasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Nucleoside Hydrolase for Leishmaniasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Leishmaniasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
visceral leishmaniasis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Leishmaniasis (Kala-Azar) - Dormant Projects
Leishmaniasis (Kala-Azar) - Discontinued Products
Leishmaniasis (Kala-Azar) - Product Development Milestones
Featured News & Press Releases
Dec 15, 2015: U.S. Issues Patent on Corifungin
Oct 26, 2015: iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program
Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions
Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients
Feb 26, 2013: National Institutes of Health Supports Acea’s Research
Mar 06, 2012: ?10 million boost for neglected tropical disease research at Dundee
Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis
Oct 24, 2011: iCo Therapeutics Oral Amphotericin B Delivery System To Be Presented At AAPS
Jul 01, 2011: FDA issues orphan-drug designation to Corifungin
Sep 29, 2010: iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status
Feb 10, 2010: Dr. Jose Vazquez presents poster at ICAAC
Dec 14, 2005: Collaboration on the Development of Anti-Parasitic Drugs for Both Malaria and Leishmaniasis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 102

LIST OF TABLES

Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2016
Number of Products under Development for Leishmaniasis (Kala-Azar) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Leishmaniasis (Kala-Azar) - Pipeline by Advinus Therapeutics Ltd, H2 2016
Leishmaniasis (Kala-Azar) - Pipeline by BioLingus AG, H2 2016
Leishmaniasis (Kala-Azar) - Pipeline by iCo Therapeutics Inc., H2 2016
Leishmaniasis (Kala-Azar) - Pipeline by Laboratorios LETI S.L., H2 2016
Leishmaniasis (Kala-Azar) - Pipeline by ManRos Therapeutics, H2 2016
Leishmaniasis (Kala-Azar) - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016
Leishmaniasis (Kala-Azar) - Pipeline by Nanomerics Ltd, H2 2016
Leishmaniasis (Kala-Azar) - Pipeline by Novartis AG, H2 2016
Leishmaniasis (Kala-Azar) - Pipeline by Oblita Therapeutics BVBA, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Leishmaniasis (Kala-Azar) - Dormant Projects, H2 2016
Leishmaniasis (Kala-Azar) - Dormant Projects (Contd..1), H2 2016
Leishmaniasis (Kala-Azar) - Discontinued Products, H2 2016 92

LIST OF FIGURES

Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2016
Number of Products under Development for Leishmaniasis (Kala-Azar) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: